EPAX® Omega 3-9-11 is rich in Omega-3 EPA and DHA – long-chain poly-unsaturated fatty acids (LC-PUFAs) well known for their benefits in areas like heart and brain health. However, unlike other Omega-3 products, it combines them with the less familiar long-chain monounsaturated fatty acids (LC-MUFAs), Omegas 9 and 11, which are increasingly being recognised for their potential in skin and metabolic health.
The first concentrated version of an oil with both LC-MUFAs and LC-PUFAs, EPAX® Omega 3-9-11 is derived from pelagic fish from the North Atlantic. As well as a healthy amount of Omega-3, they contain unusually high levels of Omega-9 and Omega-11.
The new product is produced using Epax® EQP+ Tech, a next-level distillation process, which allows Epax to isolate and increase the content of Omegas 3, 9 and 11. EPAX® Omega 3-9-11 contains a minimum of 720 mg / g of these fatty acids.
Ideal for nutraceuticals, it offers significant potential in the skin health category. EPA and DHA are capable of reducing UV-induced inflammation[1], while a pilot study by Epax has indicated that Omega-9 and Omega-11-rich cetoleic oils can reduce skin redness.
Furthermore, there is evidence that the different fatty acids in EPAX® Omega 3-9-11 may work together to deliver a complementary effect. In pre-clinical studies, metabolic health parameters were improved to a greater extent with a combination of LC-MUFAs and LC-PUFAs than with each lipid on its own.
Bjørn Refsum, CEO of Epax, said: “Omega-3 fatty acids – and all the scientific evidence of their benefits – are just the start of the story. As well as developing EPA and DHA of unmatched purity and quality, Epax has been exploring the potential of other marine lipids. EPAX® Omega 3-9-11 is a full-spectrum solution that offers the best of both worlds – the familiar, well-proven Omega-3, and the up-and-coming Omegas 9 and 11. The potential is huge and there’s much more to discover.”
Epax is supporting further research into the role of LC-MUFAs for skin health – recruitment has begun for a randomised placebo-controlled study in subjects with eczema. Epax is also proud to provide LC-MUFAs for university research into metabolic health.
References:
[1] Pilkington et al, 2011
2 Yoshinaga et al, 2021
